A new drug has been testified, which is still undergoing clinical trials, for the treatment of type 2 diabetes.
Australian scientists, in collaboration with US pharma company DiaKine Therapeutics, have found that a drug candidate, Lisofylline, could be a potential drug in the treatment of Type 2 diabetes.
Doctors from Sydney's Garvan Institute of Medical Research examined the anti-inflammatory medicine which is under clinical tests for other diseases also, on mice fed with high-fat foods.
The hormone insulin is generated after we eat to push sugar from our blood into our cells to get energy. When people put on weight, this process gets deteriorate and develop glucose intolerance, or 'insulin resistance'.
The phase 1 clinical trials have already been done on Lisofylline, and have been observed to be safe by using in healthy subjects. Now it has been undergoing Phase 2 clinical trials for several other purposes currently.
The new outcomes suggest that Lisofylline, or other medicines that might be orally bioavailable with the same verticals of activity, can prove to be a new approach to the treatment for Type 2 diabetes.
People suffering with type 2 diabetes can get better treatment now and it’s time to look forward for its certification and final approval.